Target Marketing in Pharma: Segmentation, Targeting, and Positioning

Pharma marketing audience targeting often gets reduced to "buy the top five deciles." That is a list, not a strategy. Deciles tell you who writes the most prescriptions in a category. They do not tell you who is persuadable, who has patients that fit your label, or who is blocked by payer rules. STP is how you get from the list to a choice.

Segmentation: dividing the market in ways that predict behavior

A segmentation is only useful if the groups behave differently and need different treatment. For prescribers, the useful variables usually come from four places:

• Volume and potential. How many relevant patients they see, from claims data. This is the decile.
• Current behavior. Share of your brand vs. competitors, recent new starts, switching patterns.
• Context. Specialty, practice setting, health system affiliation, payer mix in their area.
• Attitude and channel preference. From market research or field feedback: early adopter vs. conservative, rep access vs. no-see, digital engagement history.

For patients, segmentation tends to follow the patient journey: undiagnosed but symptomatic, diagnosed and untreated, treated with the current standard, and on your brand (where adherence matters). Caregivers are a separate segment in pediatric, elderly, and severe conditions. The more detailed HCP methods are in HCP segmentation models.

Targeting: choosing where the brand will compete

Targeting is where you say no to some segments. That is uncomfortable, especially with a sales force that wants every physician covered, but spreading frequency across everyone usually means nobody gets enough.

The test for each segment: if we reached these people well, how much would the forecast move, and what would it cost? A segment of loyal high-volume writers might have huge volume but little upside. A segment of mid-volume physicians using an older therapy might have more room to move. HCP tiering covers how to rank without overfitting to volume.

A hypothetical example: STP for a new atopic dermatitis brand

Imagine a hypothetical oral therapy, Brand X, approved for moderate-to-severe atopic dermatitis in adults after failure of topical treatment. All numbers below are illustrative.

Claims data show 18,000 prescribers treated relevant patients in the past 12 months. A first segmentation produces four groups:

Segments A and B together are 8,500 HCPs (47 percent of prescribers) and 80 percent of relevant patients. That is the core target. Segment B is the growth bet: physicians whose patients are stuck on topicals and who might find an oral option easier to start than an injectable. Segment D gets light, unbranded referral education, not a full branded program, because 8,000 physicians at 10 percent of patients would absorb budget with little return.

On the patient side, the brand targets adults diagnosed with eczema who are still using topicals and are frustrated with results. That audience is reached through contextual health content, search, and video, not through any individual-level health record.

Positioning: one message per priority segment, one brand story

For Brand X, the overall position might be: "for adults whose eczema is not controlled with topicals, an oral option that can be started without injections." That is only usable if the label and data support it, and medical and regulatory will check every word.

Each priority segment then gets a different emphasis on the same story:

• Segment A: efficacy and safety data relative to what they use now, presented within what the label allows.
• Segment B: how and when to escalate from topicals, monitoring requirements, and access support.
• Patients: recognizing that uncontrolled symptoms are worth raising with a dermatologist.

The point is one brand, not three. Positioning that splits into unrelated stories by audience makes the HCP and DTC tracks feel like different drugs, a problem covered in HCP vs. DTC marketing.

Turning STP into audience advertising

Audience advertising in pharma marketing is where segmentation becomes media. For HCPs, the priority segments become an NPI target list, matched to digital IDs and loaded into programmatic, email, and point-of-care platforms. Match rates vary by partner, so the reachable audience will be smaller than the list. The steps are in how to build an NPI target list.

For patients, segmentation usually becomes a mix of contextual segments, platform interest audiences where permitted, and consented first-party data from the brand site or support program. Health conditions are sensitive data. State laws such as Washington's My Health My Data Act and platform policies restrict how condition audiences can be built and used, so plan time for privacy review.

Where STP goes wrong in pharma

1. Segments that do not change the plan. If every segment gets the same channels and message, the segmentation was decoration.
2. Volume-only targeting. Top deciles are the most contested physicians in the category.
3. No refresh. Claims data shift. A target list built at launch is stale a year later.
4. Positioning written before targeting. The message ends up generic because it was not written for anyone in particular.

Practical takeaway

Take your current target list and add one column next to decile: current share of your brand. Sort by high potential and low share. The physicians at the top of that sort are your growth segment, and they deserve a different message and channel mix from the loyalists. The broader planning context is in pharmaceutical marketing strategies.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.